Does Veracyte (VCYT) Offer Both Strength and Opportunity?

1 month ago 22

Soumya Eswaran

Mon, February 23, 2026 astatine 8:25 AM CST 3 min read

Brown Capital Management, an concern absorption company, released its 4th fourth 2025 capitalist missive for “The Brown Capital Management Small Company Fund”. A transcript of the missive tin beryllium downloaded here. In the 4th fourth of 2025, the Small Company Fund (Investor shares) fell 1.50%, down the Russell 2000® Growth index's 1.22% gain. Real property and telecommunications businesses led the benchmark's show for the quarter. The Fund was down 11.46% successful 2025, importantly lagging the Index’s 13.01% return. The firm’s concern decisions are driven by institution fundamentals, and its holdings performed good successful presumption of gross and net maturation successful 2025. Please reappraisal the Fund’s apical 5 holdings to summation insights into their cardinal selections for 2025.

In its fourth-quarter 2025 capitalist letter, The Brown Capital Management Small Company Fund highlighted stocks similar Veracyte, Inc. (NASDAQ:VCYT). Headquartered successful South San Francisco, California, Veracyte, Inc. (NASDAQ:VCYT) is simply a planetary diagnostic company. On February 20, 2026, Veracyte, Inc. (NASDAQ:VCYT) banal closed astatine $35.63 per share. One-month instrumentality of Veracyte, Inc. (NASDAQ:VCYT) was -12.18%, and its shares mislaid 9.48% implicit the past 52 weeks. Veracyte, Inc. (NASDAQ:VCYT) has a marketplace capitalization of $2.817 billion.

The Brown Capital Management Small Company Fund stated the pursuing regarding Veracyte, Inc. (NASDAQ:VCYT) successful its 4th fourth 2025 capitalist letter:

"In the quarter, we added 4 companies to the Fund—AvePoint Inc. (AVPT), Loar Holdings (LOAR), PDF Solutions (PDFS) and Veracyte, Inc. (NASDAQ:VCYT). Veracyte is simply a genomic diagnostics institution that develops and delivers tests that assistance physicians diagnose and dainty crab much accurately and little invasively. Veracyte holds a ascendant marketplace presumption with much than 50% marketplace stock successful each of its halfway products: Decipher (genomic classifier for prostate cancer) and Afirma (genomic classifier for thyroid cancer). These 2 products contributed much than 90% of gross during 2024. Decipher’s marketplace is lone 40% penetrated and tin proceed to present double-digit maturation for respective years. Afirma is much penetrated but offers stability. We deliberation some products are good positioned competitively, fixed extended objective validation, aesculapian line inclusion and wide reimbursement coverage. The company’s pipeline—including Prosigna LDT (U.S. bosom cancer), Decipher IVD (international prostate), Percepta Nasal swab (lung cancer)— could grow its marketplace accidental by much than $3 billion. Veracyte turned profitable successful 2024 and has shown meaningful borderline enlargement twelvemonth to date, and we expect further enlargement from here. Veracyte features a coagulated equilibrium expanse with much than $400 cardinal successful currency and has been escaped currency travel affirmative since 2023."

Read Entire Article